Myeloproliferative Disorders Drugs/Treatment Market Size

Myeloproliferative Disorders Drugs/Treatment Market Size

Myeloproliferative Disorders Drugs/Treatment Market size was valued at USD 9.3 billion in 2023 and is expected to grow at a CAGR of 3.2% between 2024 and 2032. The market is experiencing significant growth due to the availability of novel drugs and a robust pipeline that has broadened the treatment options and stimulated innovation for rare disease treatment. Additionally, the rising incidence of myeloproliferative disorders, attributed to an aging population, changing lifestyles, and increased public awareness, further boosts market growth.

To get key market trends

  Download Free Sample

For instance, the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute estimates that approximately 20,000 people are diagnosed with a myeloproliferative neoplasm (MPN) each year in the U.S., with around 295,000 people living with an MPN. Moreover, the growing awareness about MPDs among both patients and healthcare providers is leading to early diagnosis and treatment, driving market growth.

Myeloproliferative disorder treatment refers to therapeutic interventions designed to manage and mitigate the symptoms and progression of myeloproliferative disorders, a group of rare haematological conditions characterized by the overproduction of blood cells in the bone marrow.